Effect of corticosteroids on the outcome of patients with advanced non –small cell lung cancer treated with immune-checkpoint inhibitors
We analysed patients with advanced non –small cell lung cancer (NSCLC) who were treated with immune-checkpoint inhibitors (ICIs) to address the effect of the timeline and reason for corticosteroid administration on survival outcomes. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 5, 2021 Category: Cancer & Oncology Authors: Marcus Skribek, Konstantinos Rounis, Soren Afshar, Oscar Grundberg, Signe Friesland, Georgios Tsakonas, Simon Ekman, Luigi De Petris Tags: Original Research Source Type: research

Shall we use steroids when treating patients with lung cancer with checkpoint inhibitors?
The introduction of anti-programmed cell death 1 (PD-1) or programmed death-ligand 1 (PD-L1) checkpoint inhibitors has fundamentally changed the standard of care for most patients with metastatic non –small cell lung cancer (NSCLC). It has also provided the first survival increment in extensive disease small-cell lung cancer (SCLC) for more than two decades. A common aim of these immune modulating agents is to reinvigorate the host's immune response which has been shut down by various cancer-m ediated mechanisms. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 5, 2021 Category: Cancer & Oncology Authors: Niels Reinmuth, Martin Schuler Tags: Editorial Source Type: research

Corrigendum to “A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation” [Eur J Canc 131 (2020) 68–75]
The authors regret that the author, Mengyao Li, was missed from the list of authors originally published with this article. Mengyao Li had made important contributions in performing the hands-on modelling and simulation work and analysis of data that are reported in this manuscript. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 4, 2021 Category: Cancer & Oncology Authors: Mallika Lala, Tommy Ruosi Li, Dinesh P. de Alwis, Vikram Sinha, Kapil Mayawala, Mengyao Li, Noboru Yamamoto, Lillian L. Siu, Elliot Chartash, Hesham Aboshady, Lokesh Jain Tags: Corrigendum Source Type: research

Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by Pfob et  al.
“Doctor, my tumour has disappeared- why do I need surgery?” (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 1, 2021 Category: Cancer & Oncology Authors: Peter Dubsky, Christoph Tausch Tags: Editorial Source Type: research

Nivolumab activity in advanced refractory malignant peritoneal mesothelioma
Malignant peritoneal mesothelioma is a rare neoplasm of mesothelial origin characterised by the diffuse invasion of peritoneal surfaces and a devastating prognosis. The therapeutic approach usually consists in cytoreductive surgery whenever feasible, with or without intraperitoneal or systemic perioperative chemotherapy [1]. For unresectable tumours, chemotherapy with pemetrexed and cisplatin, often in combination with bevacizumab, has become the most frequently used systemic therapy, based on the results observed in malignant pleural mesothelioma [2]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 25, 2020 Category: Cancer & Oncology Authors: Ondine Becker, Cl ément Beaulaton, Julien Masliah-Planchon, Vincent Servois, Sarah Watson Tags: Letter to the Editor Source Type: research

Cardiac magnetic resonance imaging of transient myocardial dysfunction in a patient treated with checkpoint-targeted immunotherapy
Here we report the case of a 70-year-old man presented to the emergency department because of sudden dyspnoea. Past medical history included lung cancer for which therapy with checkpoint inhibitor atezolizumab had been started a week earlier. At admission, electrocardiogram (ECG) showed mild ST-segment elevation in antero-lateral leads, while focus echocardiography revealed extensive akinesia of left ventricular mid-apical segments, more evident at septum level. Urgent coronary angiography showed patent epicardial coronary arteries. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 25, 2020 Category: Cancer & Oncology Authors: Giovanni Camastra, Luca Arcari, Federica Ciolina, Massimiliano Danti, Luca Cacciotti Tags: Letter to the Editor Source Type: research

Response to comment on “Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer”
We thank colleagues De Vincentis and Frantellizzi [1] for their thoughtful considerations on our recently published manuscript in this journal and their ongoing work on optimising patient selection for radium-223 therapy [1,2]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 25, 2020 Category: Cancer & Oncology Authors: Maarten J. van der Doelen, Peter H.J. Slootbeek, Niven Mehra Tags: Author ’s reply Source Type: research

Corrigendum to “Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)” [Eur J Canc. vol. 139 November (2020) Pages 149–168]
The authors would like to apologise for any inconvenience caused. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 19, 2020 Category: Cancer & Oncology Authors: Gabriella Ferrandina, Cynthia Aristei, Pietro R. Biondetti, Ferdinando Carlo Maria Cananzi, Paolo Casali, Francesca Ciccarone, Nicoletta Colombo, Alessandro Comandone, Renzo Corvo ’, Pierandrea De Iaco, Angelo Paolo Dei Tos, Vittorio Donato, Marco Fiore Tags: Corrigendum Source Type: research

Corrigendum to “Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group” [European Journal of Cancer. Volume 140, November 2020, Pages 1-10]
The authors regret that the spelling of the second author's name was given incorrectly in the published paper. The author ’s correct name is Jvan Casarin. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 17, 2020 Category: Cancer & Oncology Authors: Antonino Ditto, Jvan Casarin, Ciro Pinelli, Anna M. Perrone, Paolo Scollo, Fabio Martinelli, Giorgio Bogani, Umberto Leone Roberti Maggiore, Mauro Signorelli, Valentina Chiappa, Giorgio Giorda, Giuseppe Scibilia, Pierandrea De Iaco, Mariateresa Evangelist Tags: Corrigendum Source Type: research

Oropharyngeal cancer: First relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric study
Although Human Papilloma Virus (HPV)-driven oropharyngeal cancer (OPC) prognosis is significantly better than that of other head and neck cancers, up to 25% of cases will recur within 5 years. Data on the pattern of disease recurrence and efficiency of salvage treatment are still sparse. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 14, 2020 Category: Cancer & Oncology Authors: Dorian Culi é, Quentin Lisan, Charlotte Leroy, Anouchka Modesto, Renaud Schiappa, Emmanuel Chamorey, Olivier Dassonville, Gilles Poissonnet, Bruno Guelfucci, Alain Bizeau, Sebastien Vergez, Agnes Dupret-Bories, Renaud Garrel, Nicolas Fakhry, Laure Santin Tags: Original Research Source Type: research

Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study
Classification of thymic epithelial tumours (TETs) is known to be challenging; however, the level of discordances at a nationwide level between initial and expert diagnosis and their clinical consequences are currently unknown. RYTHMIC is a national network dedicated to the management of TET based on initial histological diagnosis, followed by an additional expert review of all cases. Our aim was to evaluate the discordances between initial and expert diagnoses and whether they would have led to different clinical management. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 12, 2020 Category: Cancer & Oncology Authors: Thierry J. Molina, Maria V. Bluthgen, Lara Chalabreysse, Vincent T. de Montpr éville, Anne de Muret, Romain Dubois, Véronique Hofman, Sylvie Lantuejoul, Cécile le Naoures, Audrey Mansuet-Lupo, Marie Parrens, Nicolas Piton, Isabelle Rouquette, Véroniqu Tags: Original Research Source Type: research

Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools
Liquid biopsy provides real-time data about prognosis and actionable mutations in metastatic breast cancer (MBC). The aim of this study was to explore the combination of circulating tumour DNA (ctDNA) analysis and circulating tumour cells (CTCs) enumeration in estimating target organs more susceptible to MBC involvement. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 8, 2020 Category: Cancer & Oncology Authors: Lorenzo Gerratana, Andrew A. Davis, Maurizio Polano, Qiang Zhang, Ami N. Shah, Chenyu Lin, Debora Basile, Giuseppe Toffoli, Firas Wehbe, Fabio Puglisi, Amir Behdad, Leonidas C. Platanias, William J. Gradishar, Massimo Cristofanilli Tags: Original Research Source Type: research

Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy
Neoadjuvant systemic treatment elicits a pathologic complete response (pCR) in about 35% of women with breast cancer. In such cases, breast surgery may be considered overtreatment. We evaluated multivariate algorithms using patient, tumor, and vacuum-assisted biopsy (VAB) variables to identify patients with breast pCR. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 8, 2020 Category: Cancer & Oncology Authors: Andr é Pfob, Chris Sidey-Gibbons, Han-Byoel Lee, Marios Konstantinos Tasoulis, Vivian Koelbel, Michael Golatta, Gaiane M. Rauch, Benjamin D. Smith, Vicente Valero, Wonshik Han, Fiona MacNeill, Walter Paul Weber, Geraldine Rauch, Henry M. Kuerer, Joerg He Tags: Original Research Source Type: research

The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group
Established prognostic indicators in rhabdomyosarcoma (RMS), the most common childhood soft tissue sarcoma, include several clinicopathologic features. Among pathologic features, anaplasia has been suggested as a potential prognostic indicator, but the clinical significance of anaplasia remains unclear. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 7, 2020 Category: Cancer & Oncology Authors: Archana Shenoy, Elysia Alvarez, Yueh-Yun Chi, Minjie Li, Jack F. Shern, Javed Khan, Susan M. Hiniker, Candace F. Granberg, Douglas S. Hawkins, David M. Parham, Lisa A. Teot, Erin R. Rudzinski Tags: Original Research Source Type: research

Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer
The predictive value of immune monitoring with circulating CD8+ T lymphocytes for treatment response to programmed cell death protein 1 (PD-1) inhibitors has not been explored in non-small-cell lung cancer (NSCLC), prompting us to investigate whether dynamic changes in PD-1+CD8+ T lymphocytes have predictive value for durable clinical benefit (DCB) and survival after PD-1 blockade. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 7, 2020 Category: Cancer & Oncology Authors: Chang Gon Kim, Min Hee Hong, Kyung Hwan Kim, In-Ho Seo, Beung-Chul Ahn, Kyoung-Ho Pyo, Chun-Bong Synn, Hong In Yoon, Hyo Sup Shim, Yong Il Lee, Seong Jin Choi, Yun Jeong Lee, Ellen Janine Kim, Youngun Kim, Jeong-Eun Kwak, Jaehyung Jung, Su-Hyung Park, Soo Tags: Original Research Source Type: research

Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study
Pancreatic cancer (PC) ranks among the deadliest malignancies worldwide. In the MPACT study, first-line nab-paclitaxel plus gemcitabine (nab-P/G) demonstrated activity (median overall survival [OS], 8.7 months) and tolerability in patients with metastatic PC (mPC). However, the clinical evidence of nab-P/G in the elderly (>70 years), who account for the majority of patients with mPC, is limited. This is the first prospective, multicentre, non-interventional study evaluating the tolerability and effectiveness of nab-P/G in younger ( ≤70 years) versus elderly (>70 years) patients with mPC in the daily clinical routi...
Source: European Journal of Cancer - December 6, 2020 Category: Cancer & Oncology Authors: Gerald W. Prager, Leopold Oehler, Armin Gerger, Brigitte Mlineritsch, Johannes Andel, Andreas Petzer, Klaus Wilthoner, Thamer Sliwa, Petra Pichler, Thomas Winder, Sonja Heibl, Birgit Gruenberger, Friedrich Laengle, Eva Hubmann, Markus Korger, Martin Peche Tags: Original Research Source Type: research

CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment
Cryoablation demonstrated feasibility in progressive DT pts. The study met is primary end-point with 86% of non-progressive disease at +12  months, with reduced pain, better functional status, and encouraging long-term disease control. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 5, 2020 Category: Cancer & Oncology Authors: Jean-Emmanuel Kurtz, Xavier Buy, Fr édéric Deschamps, Erik Sauleau, Amine Bouhamama, Maud Toulmonde, Charles Honoré, François Bertucci, Mehdi Brahmi, Christine Chevreau, Florence Duffaud, Justine Gantzer, Julien Garnon, Jean-Yves Blay, Afshin Gangi Tags: Original Research Source Type: research

Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study
The management of cervical cancer patients with intraoperative detection of lymph node involvement remains controversial. Since all these patients are referred for (chemo)radiation after the surgery, the key decision is whether radical hysterectomy should be completed as originally planned, taking into account an additional morbidity associated with extensive surgical dissection prior to adjuvant treatment. The ABRAX study investigated whether completing a radical uterine procedure is associated with an improved oncological outcome of such patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 5, 2020 Category: Cancer & Oncology Authors: D. Cibula, L. Dostalek, P. Hillemanns, G. Scambia, J. Jarkovsky, J. Persson, F. Raspagliesi, Z. Novak, A. Jaeger, M.E. Capilna, V. Weinberger, J. Klat, R.L. Schmidt, A. Lopez, G. Scibilia, R. Pareja, A. Kucukmetin, L. Kreitner, A. El-Balat, G.J.R. Pereira Tags: Original Research Source Type: research

Dabrafenib –trametinib combination therapy re-challenge in advanced BRAFV600E-mutant non–small-cell lung cancer
We read with great interest the article by Facchinetti et  al. [1] about the molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E-mutant non–small-cell lung cancer (NSCLC). The article indicates that understanding the mechanisms of acquired resistance to BRAF and MEK inhibitors in NSCLC is important to discover novel treatment stra tegies. Currently, it is difficult for clinicians to perform molecular re-analysis in the real world. Here, we report the case of achieving a long-term partial response (PR) to dabrafenib-trametinib combination therapy (D/T) re-challenge in advanced BRAFV600E-mut...
Source: European Journal of Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Fumihiro Kashizaki, Arihito Tanaka, Shigeaki Hattori, Shunsuke Sugimoto Tags: Letter to the Editor Source Type: research

Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group
Conjunctival melanoma (CM) represents about 5% of all ocular melanomas with an incidence of 0.2 –0.8 per million [1]. It significantly differs from uveal melanoma (UM) and more closely resembles cutaneous melanoma. CM spreads via lymphogeneous and hematogeneous dissemination [2] and shows a clear UV light signature and high mutational burden [3]. BRAF, NRAS and KIT mutations are detected in up to 50%, 20% and 7%, respectively [2,4]. Primary tumours are mostly treated by local excision [5–7], often combined with adjuvant interventions [5,7,8]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Anja Wessely, Theresa Steeb, Carola Berking, Max Schlaak, Markus V. Heppt, German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma) Tags: Letter to the Editor Source Type: research

Consideration regarding immune checkpoint inhibitor –induced secondary adrenal insufficiency in patients lacking human leucocyte antigen-DR15
We read the article entitled ‘Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency’ by Seiichi Yano et al. [1] with great interest. The authors reported significantly higher prevalence of human leucocyte antigen (HLA)-DR15, B52, and Cw12 in 11 pa tients with immune checkpoint inhibitor (ICPi)–induced secondary adrenal insufficiency as compared with Japanese healthy controls. Furthermore, they presented the possibility of HLA-DR15 as a predictive marker of a pituitary immune-related adverse event (irAE). (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Akinori Kanzaki, Taiichirou Otsuki, Tohru Arii, Hidenori Koyama, Satoru Katayama Tags: Letter to the Editor Source Type: research

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial
In IRPC, the addition of 6 months of ADT to RT70 or DERT76 significantly improves BF and appears to decrease the risk of death from prostate cancer compared with DERT76 alone with no difference in OS. In the setting of IRPC, ADT plus RT 70  Gy yields effective disease control with a better GI toxicity profile.Clinicaltrials.gov#NCT00223145. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Abdenour Nabid, Nathalie Carrier, Eric Vigneault, Thu Van Nguyen, Peter Vavassis, Marc-Andr é Brassard, Boris Bahoric, Robert Archambault, François Vincent, Redouane Bettahar, Derek Wilke, Luis Souhami Tags: Original Research Source Type: research

Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach
The interplay between cancer cells and the immune system has offered a new field of research and multiple novel therapeutic opportunities. In particular, the interaction of programmed death 1 (PD-1) receptor expressed by immune cells and its ligand (PD-L1) expressed by cancer cells is a well-known mechanism of cancers' immune escape [1]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Andrea De Giglio, Marta Scorsetti, Davide Franceschini, Francesco Massari, Andrea Ardizzoni Tags: Letter to the Editor Source Type: research

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
We report results of the 20-patient safety run-in. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Alice Boil ève, Marc Hilmi, Paul Gougis, Romain Cohen, Benoît Rousseau, Jean-Frédéric Blanc, Meher Ben Abdelghani, Hélène Castanié, Laëtitia Dahan, David Tougeron, Jean-Philippe Metges, Christophe Tournigand, Marie-Line Garcia-Larnicol, Dewi Verne Tags: Original Research Source Type: research

Exome sequencing identifies a recurrent variant in SERPINA3 associating with hereditary susceptibility to breast cancer
Breast cancer is strongly influenced by hereditary risk factors. Yet, the known susceptibility genes and genomic loci explain only about half of the familial component of the disease. To identify novel breast cancer predisposing gene defects, here we have performed massive parallel sequencing for Northern Finnish breast cancer cases. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Susanna Koivuluoma, Anna Tervasm äki, Saila Kauppila, Robert Winqvist, Timo Kumpula, Outi Kuismin, Jukka Moilanen, Katri Pylkäs Tags: Original Research Source Type: research

Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al
We were very impressed by the interesting and intriguing work of van der Doelen et  al. [1] recently published in your Journal . This inspires some considerations that we would gladly share with the scientific community. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 3, 2020 Category: Cancer & Oncology Authors: Giuseppe De Vincentis, Viviana Frantellizzi Tags: Letter to the Editor Source Type: research

Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I –III patients
The purpose of this study was to validate the results of an 11-gene expression profiling (GEP) assay which aims to improve the precision of individual prognosis beyond conventional American Joint Committee on Cancer staging for patients with cutaneous melanoma. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 2, 2020 Category: Cancer & Oncology Authors: Thilo Gambichler, Konstantinos Tsagoudis, Felix Kiecker, Uwe Reinhold, Eggert Stockfleth, Rami Hamscho, Friederike Egberts, Axel Hauschild, Teresa Amaral, Claus Garbe Tags: Original Research Source Type: research

Development and validation of a pancreatic cancer risk model for the general population using electronic health records: An observational study
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at a late, incurable stage. We sought to determine whether individuals at high risk of developing PDAC could be identified early using routinely collected data. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 2, 2020 Category: Cancer & Oncology Authors: Limor Appelbaum, Jos é P. Cambronero, Jennifer P. Stevens, Steven Horng, Karla Pollick, George Silva, Sebastien Haneuse, Gail Piatkowski, Nordine Benhaga, Stacey Duey, Mary A. Stevenson, Harvey Mamon, Irving D. Kaplan, Martin C. Rinard Tags: Original Research Source Type: research

Financial toxicity and cancer treatments: Help from biosimilars  – The explanatory case of bevacizumab
Biologics are often high-cost components of oncology care. Biosimilars have the potential to reduce the costs of biologics. Considering that switching treatment from reference product to biosimilar is supported by most available data and post-marketing pharmacovigilance programmes are warranted, it results that biosimilar cancer treatment are not just about the direct cost savings, but also for to incentivise the evaluation and/or clinical use of new treatment approaches and novel drugs. In facts, European Union (EU) guidelines have resulted in the approval of biosimilar therapeutics with comparable efficacy and safety pro...
Source: European Journal of Cancer - December 2, 2020 Category: Cancer & Oncology Authors: Jacopo Giuliani, Francesco Fiorica, Vito Albanese, Andrea Bonetti Tags: Letter to the Editor Source Type: research

Cancers emerging early in adulthood: Analysis of trends and patterns in European cancer registries
Cancer prevention efforts seem to have favourably impacted intermediate- and late-age emerging cancer incidence rates. For early-age emerging cancers, aetiological research is needed to identify exposures and stressors occurring early in life, especially for those cancers that have been increasing in young adults. This knowledge will be essential to develop preventive strategies. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 2, 2020 Category: Cancer & Oncology Authors: Ghislaine Scelo, Milena M. Maule, Lorenzo Richiardi Tags: Original Research Source Type: research

Association of phosphoenolpyruvate carboxykinase 1 protein kinase activity-dependent sterol regulatory element-binding protein 1 activation with prognosis of oesophageal carcinoma
Metabolic enzymes have non-canonical functions and play vital roles in the regulation of various cellular activities. Phosphoenolpyruvate carboxykinase 1 (PCK1), a gluconeogenic enzyme, was recently identified as an AKT-dependent protein kinase and promoted sterol regulatory element-binding protein 1 (SREBP1) –dependent lipogenesis. However, association of this protein kinase activity of PCK1 with progression of oesophageal squamous cell carcinoma (ESCC) is unclear. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 2, 2020 Category: Cancer & Oncology Authors: Fei Shao, Xueli Bian, Hongfei Jiang, Gaoxiang Zhao, Lei Zhu, Daqian Xu, Shuai Wang, Wei Guo, Dongming Xing, Qi Xue, Yibo Gao, Jie He, Zhimin Lu Tags: Original Research Source Type: research

The spleen as an organ at risk in paediatric radiotherapy: A SIOP-Europe Radiation Oncology Working Group report
Radiation may cause long-term splenic dysfunction, risking potentially fatal late sepsis. We aimed to review this complication's magnitude in paediatric radiotherapy  and gauge the level of awareness of the spleen as an organ at risk. (Source: European Journal of Cancer)
Source: European Journal of Cancer - December 1, 2020 Category: Cancer & Oncology Authors: Niruthiga Arunagiri, Sarah M. Kelly, Cathy Dunlea, Olivia Dixon, Jessica Cantwell, Pravesh Bhudia, Tom Boterberg, Geert O. Janssens, Jennifer E. Gains, Yen-Ch'ing Chang, Mark N. Gaze, SIOP-Europe Radiation Oncology Working Group Tags: Original Research Source Type: research

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry
Currently, a second dramatic upsurge of SARS-CoV-2 infection rates is observed across Europe, and there is an urgent need to clarify the imminent risk for our melanoma patients under immune checkpoint inhibition (ICI). To this aim, we reviewed the clinical course of disease for all patients included in the registry of the German working group of dermato-oncology (ADOreg, www.hautkrebsregister.de) database with confirmed SARS-CoV-2 infection. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 28, 2020 Category: Cancer & Oncology Authors: Rose K.C. Moritz, Ralf Gutzmer, Lisa Zimmer, Friedegund Meier, Misbah S. Ahmed, Sabine Sell, Max Schlaak, Florian Kapp, Michael M. Sachse, Sebastian Haferkamp, Julia Welzel, Katharina C. K ähler, Michael Weichenthal Tags: Letter to the Editor Source Type: research

SARS-CoV-2 infections in melanoma patients treated with PD-1-inhibitors- a survey of the German ADOREG melanoma registry.
Currently, a second dramatic upsurge of SARS-CoV-2 infection rates is observed across Europe and there is an urgent need to clarify the imminent risk for our melanoma patients under immune checkpoint inhibition (ICI). To this aim we reviewed the clinical course of disease for all patients included in the registry of the German working group of dermato-oncology (ADOreg, www.hautkrebsregister.de) database with confirmed SARS-CoV-2 infection. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 28, 2020 Category: Cancer & Oncology Authors: Rose K.C. Moritz, Ralf Gutzmer, Lisa Zimmer, Friedegund Meier, Misbah S. Ahmed, Sabine Sell, Max Schlaak, Florian Kapp, Michael M. Sachse, Sebastian Haferkamp, Julia Welzel, Katharina K ähler, Michael Weichenthal Tags: Letter to the Editor Source Type: research

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program
This study (CABOREAL) reports treatment patterns and outcomes for patients treated with cabozantinib through the French Early Access Program. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 27, 2020 Category: Cancer & Oncology Authors: Laurence Albiges, Aude Fl échon, Christine Chevreau, Delphine Topart, Gwenaëlle Gravis, Stéphane Oudard, Jean M. Tourani, Lionnel Geoffrois, Emeline Meriaux, Antoine Thiery-Vuillemin, Philippe Barthélémy, Sylvain Ladoire, Brigitte Laguerre, Valérie Tags: Original Research Source Type: research

Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK)
Extracranial rhabdoid tumours are rare, highly aggressive malignancies primarily affecting young children. The EU-RHAB registry was initiated in 2009 to prospectively collect data of rhabdoid tumour patients treated according to the EU-RHAB therapeutic framework. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 27, 2020 Category: Cancer & Oncology Authors: Karolina Nemes, Susanne Bens, Denis Kachanov, Margarita Teleshova, Peter Hauser, Thorsten Simon, Stephan Tippelt, Wilhelm Woessmann, Olaf Beck, Christian Flotho, Lorenz Grigull, Pablo H. Driever, Paul-Gerhardt Schlegel, Claudia Khurana, Kathrin Hering, Re Tags: Original Research Source Type: research

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non –small cell lung cancer: A real-world multicentre study
The PACIFIC trial demonstrated that durvalumab therapy following chemoradiation (CRT) was associated with improved overall survival (OS) in patients with stage III non –small cell lung cancer (NSCLC). It is unclear whether the results obtained as part of randomised controlled trials are a reflection of real-world (RW) data. Several questions remain unanswered with regard to RW durvalumab use, such as optimal time to durvalumab initiation, incidence of pneumoniti s and response in PD-L1 subgroups. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 24, 2020 Category: Cancer & Oncology Authors: Antoine Desilets, F élix Blanc-Durand, Sally Lau, Taiki Hakozaki, Rui Kitadai, Julie Malo, Wiam Belkaid, Corentin Richard, Meriem Messaoudene, Lena Cvetkovic, Suzanne Kazandjian, Mustapha Tehfe, Marie Florescu, Kevin Jao, Nathalie Daaboul, Scott Owen, Be Tags: Original Research Source Type: research

Successful toxicity reduction during delayed intensification in the non-high-risk arm of Malaysia-Singapore Acute Lymphoblastic Leukaemia 2010 study
In non –high-risk (non-HR) patients, the Malaysia-Singapore Acute Lymphoblastic Leukaemia 2003 (MS2003) study achieved good outcomes. However, its delayed-intensification (DI) phase, comprising repeated blocks of protocol III (2003-PIII), was toxic and caused significant treatment delays. The successor M S2010 study attempted to lower DI toxicity by replacing myelosuppressive drugs (doxorubicin, cytarabine) with vincristine and asparaginase. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 24, 2020 Category: Cancer & Oncology Authors: Bernice L.Z. Oh, Shawn H.R. Lee, Koon M. Foo, Kean H. Chiew, Zelia Z.L. Seeto, Zhi W. Chen, Cheryl C.C. Neoh, Germaine S.M. Liew, Jing J. Eng, Joyce C.M. Lam, Yiong H. Chan, Thuan C. Quah, Ah M. Tan, Allen E.J. Yeoh Tags: Original Research Source Type: research

Efficacy of cancer vaccines in selected gynaecological breast and ovarian  cancers: A 20-year systematic review and meta-analysis
Therapeutic cancer vaccination is an area of interest, even though promising efficacy has not been demonstrated so far. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 19, 2020 Category: Cancer & Oncology Authors: U. Dafni, S. Mart ín-Lluesma, K. Balint, Z. Tsourti, K. Vervita, J. Chenal, G. Coukos, K. Zaman, A. Sarivalasis, L.E. Kandalaft Tags: Review Source Type: research

Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life
For the majority of older women with early ER+  breast cancer, surgery is oncologically superior to PET. In less fit, older women, with characteristics similar to the matched cohort of this study (median age 81 with higher comorbidity and functional impairment burdens, the BCSS survival differential disappears at least out to 4–5 year follow- up, suggesting that for those with less than 5-year predicted life-expectancy (>90 years or>85 with comorbidities or frailty) individualised decision making regarding PET versus S+ET may be appropriate and safe to offer. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 18, 2020 Category: Cancer & Oncology Authors: Lynda Wyld, Malcolm W.R. Reed, Jenna Morgan, Karen Collins, Sue Ward, Geoffrey R. Holmes, Mike Bradburn, Stephen Walters, Maria Burton, Esther Herbert, Kate Lifford, Adrian Edwards, Alistair Ring, Thompson Robinson, Charlene Martin, Tim Chater, Kirsty Pem Tags: Clinical Trial Source Type: research

Maintenance therapy in patients with mycosis fungoides or S ézary syndrome: A neglected topic
In advanced-stage cutaneous T-cell lymphoma (CTCL), the current therapeutic options rarely provide long-lasting responses, leaving allogenic stem-cell transplantation the only potentially curative option for highly selected patients. Until today, there are no standardised strategies for maintenance therapy in patients with CTCL who achieved disease control. Moreover, evidence-based treatment options or drugs that are approved for maintenance treatment in advanced stages after remission induction are still lacking. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 17, 2020 Category: Cancer & Oncology Authors: Rudolf Stadler, Julia J. Scarisbrick Tags: Review Source Type: research

Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications
The interpretation of lymph-vascular space invasion (LVSI) is usually qualitative, as presence or absence. The aim of this study is to investigate the prognostic role of LVSI in patients affected by endometrial cancer, when evaluated with a semiquantitative analysis. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 17, 2020 Category: Cancer & Oncology Authors: Stefano Restaino, Lucia Tortorella, Giorgia Dinoi, Gian-Franco Zannoni, Alessandro Baroni, Ilaria Capasso, Ettore Distefano, Giulio Sozzi, Vito Chiantera, Giovanni Scambia, Francesco Fanfani Tags: Original Research Source Type: research

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
Concomitant medications are known to impact on clinical outcomes of patients treated with immune checkpoint inhibitors (ICIs). We aimed weighing the role of different concomitant baseline medications  to create a drug-based prognostic score. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 16, 2020 Category: Cancer & Oncology Authors: Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, Marcello Tiseo, Marco Tucci, Vincenzo Adamo, Luigia S. Stucci, Alessandro Russo, Enrica T. Tanda, Francesco Spagnolo, Francesca Rastelli, Federica Pergolesi, Daniele Santini, Marco Russano, Cecilia Ane Tags: Original Research Source Type: research

How to manage patients with corticosteroids in oncology in the era of immunotherapy?
Corticosteroids are among the most prescribed drugs in oncology. The indications range from cancer-related indications for refractory symptoms, anti-cancer effects mainly in hematology, supportive measures for cancer-specific treatments  and more recently immune-related adverse events induced by modern immunotherapies. In oncological emergencies, corticosteroids are common first-line treatments because of their rapid effect and wide variety of actions. In the last 5 years, with the advance of immune checkpoint inhibitors, corticos teroids are becoming routinely used to manage immune-related adverse effects. (Source: E...
Source: European Journal of Cancer - November 16, 2020 Category: Cancer & Oncology Authors: Mihaela Aldea, Emeline Orillard, Laura Mansi, Aur élien Marabelle, Florian Scotte, Olivier Lambotte, Jean-Marie Michot Tags: Review Source Type: research

Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia
The brain is a common site of metastatic disease for patients with advanced melanoma. Brain metastasis portends a poor prognosis, often causing deterioration in neurological function and quality of life, and leading to neurological death. Treatment approaches including surgery, radiotherapy and systemic therapy can lead to better control of this problem. Therefore, appropriate guidelines for the management of melanoma brain metastases need to be established, with regular updating when new treatment options become available. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 15, 2020 Category: Cancer & Oncology Authors: Angela M. Hong, Cora Waldstein, Brindha Shivalingam, Matteo S. Carlino, Victoria Atkinson, Richard F. Kefford, Grant A. McArthur, Alexander M. Menzies, John F. Thompson, Georgina V. Long Tags: Original Research Source Type: research

Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses
Despite intensive treatment protocols and recent advances, neuroblastomas still account for approximately 15% of all childhood cancer deaths. In contrast with adult cancers, p53 pathway inactivation in neuroblastomas is rarely caused by p53 mutation  but rather by altered MDM2 or p14ARF expression. Moreover, neuroblastomas are characterised by high proliferation rates, frequently triggered by pRb pathway dysfunction due to aberrant expression of cyclin D1, CDK4 or p16INK4a. Simultaneous disturbance of these pathways can occur via co-amplificat ion of MDM2 and CDK4 or homozygous deletion of CDKN2A, which encodes both p...
Source: European Journal of Cancer - November 12, 2020 Category: Cancer & Oncology Authors: Nil A. Schubert, Linda Schild, Stijn van Oirschot, Kaylee M. Keller, Lindy K. Alles, Lindy Vernooij, Marloes E. Nulle, M. Emmy M. Dolman, Marlinde L. van den Boogaard, Jan J. Molenaar Tags: Original Research Source Type: research

Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review
There is no consensus on the optimal systemic conversion therapy in patients with unresectable colorectal cancer liver-only metastases (CRLM) to achieve a complete resection. Interpretation of trials is complicated by heterogeneity of patients caused by emerging prognostic and predictive characteristics, such as RAS/BRAF mutation status, lack of consensus on unresectability criteria and lack of data on clinical outcome of secondary resections. A systematic review was performed of characteristics of study populations and methodology of trials regarding patients with initially unresectable colorectal cancer liver-only metast...
Source: European Journal of Cancer - November 12, 2020 Category: Cancer & Oncology Authors: Karen Bolhuis, Milan Kos, Martijn G.H. van Oijen, Rutger-Jan Swijnenburg, Cornelis J.A. Punt Tags: Review Source Type: research

Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity
Severe neurological and endocrine toxicities are well recognised adverse events of immune checkpoint inhibitors. However, the underlying pathophysiology is poorly understood, and classical circulating markers are often non-informative, making it difficult to obtain a precise diagnosis and to initiate timely and effective treatment. Here we investigated immune-modulating activity in the plasma of a mesothelioma patient who developed fatal neuroendocrine toxicity characterised by insulin-dependent diabetes, hypophisitis and a myasthenia-like syndrome while on treatment with the dual PD1 and TIM3 blockade. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 11, 2020 Category: Cancer & Oncology Authors: Luca Mazzarella, Silvia Giugliano, Paolo D'Amico, Carmen Belli, Bruno Achutti Duso, Maria Rescigno, Giuseppe Curigliano Tags: Original Research Source Type: research

Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2 –targeted treatments: Results from the french personalized reimbursement model database (2011–2018)
There is a growing need for real-world data on cancer treatments usage, especially to assess compliance with recommendations. We developed a French project using hospital data to analyse evolution in the therapeutic strategies implemented in patients with human epidermal growth factor receptor 2 (HER2) –overexpressed (HER2+) breast cancer (BC) and exposed to injectable HER2-targeted therapies, i.e. trastuzumab, pertuzumab or trastuzumab emtansine (T-DM1). (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 8, 2020 Category: Cancer & Oncology Authors: Paul Cottu, Bruno Coudert, David Perol, Anne Doly, Julien Manson, Olivier Aujoulat, Hugues Barletta, Nassera Chalabi, Laurence Samelson, Xavier Pivot Tags: Original Research Source Type: research

Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer
Our study aimed to evaluate the efficacy and resistance mechanisms of first-line epidermal growth factor receptor (EGFR) inhibitor therapy in patients with advanced non –small-cell lung cancer (NSCLC) harbouring uncommon EGFR exon 19 deletion-insertion (19delins) variants. (Source: European Journal of Cancer)
Source: European Journal of Cancer - November 7, 2020 Category: Cancer & Oncology Authors: Xingzhou Peng, Xiaoyan Long, Li Liu, Liang Zeng, Haiyan Yang, Wenjuan Jiang, Dehua Liao, Kunyan Li, Jing Wang, Analyn Lizaso, Xinru Mao, Qinqin Xu, Aaron S. Mansfield, Nong Yang, Yongchang Zhang Tags: Original Research Source Type: research